Web of Science: 17 cites, Scopus: 22 cites, Google Scholar: cites,
Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in highrisk populations, Spain, 2016
Martínez-Gómez, Xavier (Hospital Universitari Vall d'Hebron)
Curran, Adrian (Hospital Universitari Vall d'Hebron)
Campins Martí, Magda (Hospital Universitari Vall d'Hebron)
Alemany, L. (Institut Català d'Oncologia)
Rodrigo-Pendás, J.Á. (Hospital Universitari Vall d'Hebron)
Borruel, Natalia (Hospital Universitari Vall d'Hebron)
Castellsagué, X. (Institut Català d'Oncologia)
Díaz de Heredia, Cristina (Hospital Universitari Vall d'Hebron)
Moraga-Llop, F.A. (Asociación Española de Vacunología)
del Pino, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Torné, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Universitat Autònoma de Barcelona

Data: 2019
Resum: Introduction: Although human papillomavirus (HPV) routine vaccination programmes have been implemented around the world and recommendations have been expanded to include other high-risk individuals, current recommendations often differ between countries in Europe, as well as worldwide. Aim: To find and summarise the best available evidence of HPV vaccination in high-risk patients aiding clinicians and public health workers in the day-to-day vaccine decisions relating to HPV in Spain. Methods: We conducted a systematic review of the immunogenicity, safety and efficacy/effectiveness of HPV vaccination in high-risk populations between January 2006 and June 2016. HPV vaccination recommendations were established with levels of evidence according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Results: A strong recommendation about HPV vaccination was made in the following groups: HIV infected patients aged 9-26 years; men who have sex with men aged 9-26 years; women with precancerous cervical lesions; patients with congenital bone marrow failure syndrome; women who have received a solid organ transplant or hematopoietic stem cell transplantation aged 9-26 years; and patients diagnosed with recurrent respiratory papillomatosis. Conclusions: Data concerning non-routine HPV vaccination in populations with a high risk of HPV infection and associated lesions were scarce. We have developed a document to evaluate and establish evidence- based guidelines on HPV vaccination in highrisk populations in Spain, based on best available scientific evidence.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article de revisió ; Article ; Versió publicada
Matèria: Evidence-based medicine ; Human papillomavirus infection ; HPV ; Vaccines ; Immunisation ; High-risk populations ; HIV infection ; HIV ; Men who have sex with men ; MSM
Publicat a: Eurosurveillance, Vol. 24 Núm. 7 (14 2019) , p. 1700857, ISSN 1560-7917

DOI: 10.2807/1560-7917.ES.2019.24.7.1700857
PMID: 30782268


14 p, 278.2 KB

El registre apareix a les col·leccions:
Articles > Articles publicats

 Registre creat el 2020-06-03, darrera modificació el 2022-03-26



   Favorit i Compartir